Abstract
Combining contrast-enhanced CT (CECT) imaging features and clinical characteristics is an effective method for preoperatively identifying macrotrabecular-massive hepatocellular carcinoma (MTM-HCC), even in early-stage patients. The clinical-radiologic (CR) model developed in this study demonstrates high predictive performance and could potentially guide decision-making regarding aggressive therapies in MTM-HCC patients.
Introduction
Hepatocellular carcinoma (HCC) is a heterogeneous disease with various histological subtypes. Among these, the macrotrabecular-massive (MTM) subtype, recognized by the WHO in 2019, is particularly aggressive, associated with high recurrence rates and poor survival. Currently, definitive diagnosis requires postoperative pathological examination or invasive biopsy. There is a critical clinical need for non-invasive, preoperative methods to identify MTM-HCC using standard diagnostic tools like CT scans and blood markers.
Materials and Methods
This retrospective study analyzed 101 patients with pathology-proven HCC (35 MTM and 66 non-MTM) treated at The Second Affiliated Hospital, South China University of Technology, between January 2017 and November 2021.
Researchers evaluated three predictive models:
- Clinical (C) Model: Utilized blood biomarkers including alpha-fetoprotein (AFP) and hemoglobin (HGB).
- Radiologic (R) Model: Based on CT features within the LI-RADS (Liver Imaging Reporting and Data System) framework.
- Clinical-Radiologic (CR) Model: A hybrid model combining significant predictors from both clinical and radiologic data.
Results
The combined CR model demonstrated superior predictive performance compared to individual models, achieving an Area Under the Curve (AUC) of 0.793. Notably, in the subgroup of patients with early-stage disease (BCLC 0-A), the model's performance remained robust with an AUC of 0.801.
Multivariate analysis identified four independent predictors for MTM-HCC:
- High Serum AFP (≥ 228 ng/mL; OR = 4.101)
- High Hemoglobin (≥ 130.5 g/L; OR = 3.943)
- Absence of an enhancing capsule (OR = 3.274)
- Intratumor hypoenhancement (OR = 2.724)
Discussion
The association between high hemoglobin and MTM-HCC is a notable finding, potentially linked to tumor hypoxia-induced erythropoietin expression and angiogenesis. Radiologically, the absence of an enhancing capsule and the presence of intratumor hypoenhancement serve as indicators of tumor invasiveness and internal necrosis, respectively. Identifying these features preoperatively allows for the detection of aggressive subtypes even in early-stage patients, potentially shifting treatment strategies toward more aggressive surgical margins or intensive surveillance.
Conclusion
The CR model provides a non-invasive and effective tool for the preoperative prediction of MTM-HCC. While limited by its retrospective, single-center design and small sample size, the study highlights the potential of combining imaging and clinical data to improve patient stratification and treatment planning. Future research incorporating radiomics or deep learning may further enhance predictive accuracy.
Summary updated